Interestingly, some incoming signaling pathways were found to be specific to one subtype of lung cancer, as exemplified by HGF (a new highlight in the treatments of lung cancer), KIT (activating the JAK/STAT and PLC/PKC signaling pathways) in LUAD, and the CSF3 and CDH5 in LUSC (Supplementary Fig. 8e). Here, PRRT2 is linked to lung cancer.